| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Cbo, COO & CCO | Chief Business Officer and COO | Chief Business Officer
1 company
Brendan Hannah is Cbo, COO & CCO at QNCX. Brendan Hannah's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $11.5M at current prices.
Historically, Brendan Hannah's trades have earned a middling insider score of 63/100 across 4 rated trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +64.1%.
Net of sales, the QNCX filings show accumulation of 110,686 shares.
Brendan Hannah has 11 Form 4 filings on record from May 2022 to January 2026, across 2 companies: Cbo, COO & CCO at IRulya Therapeutics (IRLA), 2026; Cbo, COO & CCO at Quince Therapeutics (QNCX), 2022–2025.
The 20 reported transactions were 8 option or other derivative awards, 7 open-market purchases, 3 option exercises and 2 stock awards.
Counted by filing, the open-market trades come to 2 purchases worth about $112K and no sales.
The largest open-market purchase was 71,762 shares of QNCX at an average $1.22 on August 8, 2023, about $88K. Twelve months later QNCX was down 43%.